.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Postmenopausal bone health requires risk-based assessment rather than relying only on calcium or vitamin D supplementation. Large randomized studies have shown that supplementation can modestly influence bone density but does not eliminate fracture risk and may have adverse effects when used excessively. For clinicians, prevention should combine assessment of fracture risk, adequate dietary calcium, vitamin D sufficiency, weight-bearing activity, fall prevention and pharmacologic therapy when indicated. Menopause care therefore benefits from an integrated approach rather than treating bone density as a separate problem. Women at high fracture risk may require bisphosphonates or other osteoporosis therapies based on age, prior fractures and calculated risk. The evidence supports using supplementation to correct deficiency rather than assuming that more calcium automatically produces better outcomes.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Postmenopausal bone health requires risk-based assessment rather than relying only on calcium or vitamin D supplementation. Large randomized studies have shown that supplementation can modestly influence bone density but does not eliminate fracture risk and may have adverse effects when used excessively. For clinicians, prevention should combine assessment of fracture risk, adequate dietary calcium, vitamin D sufficiency, weight-bearing activity, fall prevention and pharmacologic therapy when indicated. Menopause care therefore benefits from an integrated approach rather than treating bone density as a separate problem. Women at high fracture risk may require bisphosphonates or other osteoporosis therapies based on age, prior fractures and calculated risk. The evidence supports using supplementation to correct deficiency rather than assuming that more calcium automatically produces better outcomes.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
Last week
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
